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Abstract 
The aim of this study was to identify and characterise type II toxin-antitoxin (TA) systems in 
Burkholderiapseudomallei, the causative agent of the human disease melioidosis.  
 
8 putative TA systems were identified within the genome of B. pseudomalleiK96243. 5 of 
these were located witihn genome islands. Of the candidate toxins, BPSL0175 (RelE1) or 
BPSS1060 (RelE2) caused growth to cease when expressed in Escherichia coli, whereas 
expression of BPSS0390 (HicA) or BPSS1584 (HipA) (in an E. coli ∆hipBA background) 
caused a reduction in the number of culturable bacteria. HicA also caused growth arrest in B. 
pseudomalleiK96243∆hicAB. These toxin induced phenotypes were enhanced by an <3kDa 
extracellular factor that accumulated in the spent medium during growth. Expression of the 
cognate antitoxins could restore growth and culturability of cells. 
 
Expression of hicA in E. coli gave an increased number of persister cells in response to 
ciprofloxacin or ceftazidime. Site directed mutagenesis studies identified two key residues 
within the HicA toxin that were essential for both the reduced culturability and increased 
persistence phenotypes. Deletion of hicAB from B. pseudomalleiK96243 did not affect 
persister cell or survival frequencies compared to the wild type following treatment with a 
variety of stress conditions.  
 
Deletion of the ∆hipBAlocus from B. pseudomallei K96243 also had no affect on bacterial 
persistence or survival under the conditions tested. 
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